A:decitabine

2 trials

Sponsors

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, The General Hospital of Shenyang Military

Conditions

Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukaemia(CMML)myelody splastic syndromes or chronic myelomonocytic leukemia

Phase 4

An open-label, multicenter, prospective, Randomized Controlled Trial for Decitabine combined with arsenic trioxide and Ascorbic acid in subjects with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts (MDS-RAEB) and Chronic Myelomonocytic Leukaemia (CMML)

Active, not recruitingChiCTR-IPR-16010006

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical SciencesMyelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukaemia(CMML)

Start: 2016-12-01Updated: 2017-04-18

A multicenter, prospective, double arm clinical study for ultra low-dose decitabine combined with compound preparation of As4S4 in patients with intermediate-high risk myelodysplastic syndrome

Active, not recruitingChiCTR-IPR-17011619

The General Hospital of Shenyang Militarymyelody splastic syndromes or chronic myelomonocytic leukemia

Start: 2017-07-31Updated: 2017-06-12